Clinical Trial Update: Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM) [Phase 1]

View source ↗

Summary

Phase 1 study characterizes the kinetics of renal glucose reabsorption in response to dapagliflozin in healthy subjects and in individuals with Type 2 Diabetes …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• FARXIGA (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED